443797-96-4

Basic information

• Product Name: JNJ-7706621
• Synonyms: 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide JNJ7706621;4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide;Aurora Kinase/Cdk Inhibitor
• CAS NO: 443797-96-4
• Molecular Formula: C₁₅H₁₂F₂N₆O₃S
• Molecular Weight: 394.36
• Product Categories: Inhibitors;Inhibitor
• Mol File: 443797-96-4.mol
• Article Data: 4

Chemical Properties

• Melting Point: 149-155℃
• Boiling Point: 676.6 °C at 760 mmHg
• Flash Point: 363 °C
• Appearance: /
• Density: 1.71
• Storage Temp.: +2C to +8C
• Solubility: Soluble in DMSO at 15mg/ml
• PKA: 9.80±0.12(Predicted)
• Sensitive: Light Sensitive
• CAS DataBase Reference: JNJ-7706621(CAS DataBase Reference)
• NIST Chemistry Reference: JNJ-7706621(443797-96-4)
• EPA Substance Registry System: JNJ-7706621(443797-96-4)

Safety Data

• Hazardous Substances Data: 443797-96-4(Hazardous Substances Data)

Usage

Description

JNJ-7706621 is a dual inhibitor of cyclin-dependent kinases (CDKs) and Aurora kinases, which potently inhibits a range of CDKs and Aurora kinases in vitro. It shows selectivity for these enzymes over other receptors and kinases, and has been demonstrated to block the growth of various cancer cell lines with lower potency against normal cells. JNJ-7706621 also induces the regression of A375 melanoma human tumor xenografts in mice and is a substrate for the ATP-binding cassette transporter G2, also known as breast cancer resistance protein.

Uses

Used in Cancer Therapy:
JNJ-7706621 is used as a broad-spectrum inhibitor of cyclin-dependent kinases and aurora kinases, including CDK1/Cyclin B, CDK2/Cyclin A, CDK2/Cyclin E, Aurora-A, and Aurora-B. Its ability to induce growth suppression and mitotic defects suggests that JNJ-7706621 could be useful for cell cycle analysis and therapy of various cancers, including Ewing's sarcoma.

Upstream product

• 172935-91-0 2,6-difluorobenzoic hydrazide 
• 79463-77-7 N-cyanodiphenylcarbonimidate 
• 63-74-1 sulfanilamide 
• 700805-72-7 N-[4-(aminosulfonyl)phenyl]-N'-cyanocarbamidic acid phenyl ester 
• 51908-29-3 4-isothiocyanatobenzene sulfonamide 
• 443799-30-2 4-{3-[(3,5-dimethyl-pyrazol-1-yl)-imino-methyl]-thioureido}-benzenesulfonamide 
• 700805-72-7 phenyl-N'-cyano-N-(4-sulfamoylphenyl)carbamimidate 
• 443799-31-3 4-((5-amino-1H-1,2,4-triazol-3-yl)amino)benzenesulfonamide 
• 18063-02-0 2,6-difluorobenzoylchloride 

Downstream Products

• 863030-89-1 HCl salt of 4-[5-Amino-1-(2,6-difluoro-benzoyl)-1H-[1,2,4]triazol-3-ylamino]-benzenesulfonamide 
• 863030-90-4 HBr salt of 4-[5-Amino-1-(2,6-difluoro-benzoyl)-1H-[1,2,4]triazol-3-ylamino]-benzenesulfonamide 

Relevant articles and documents

Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3

Tyrosine kinase 2 (TYK2) is required for signaling of interleukin-23 (IL-23), which plays a key role in rheumatoid arthritis. Presented is the design and synthesis of 1,2,4-triazoles, and the evaluation of their inhibitory activity against the Janus associated kinases TYK2 and JAKs 1-3.

PROCESS FOR THE PREPARATION OF SUBSTITUTED TRIAZOLE COMPOUNDS

The present invention is directed to a novel process for the preparation of substituted triazole compounds, useful in the treating or ameliorating a selective kinase or dual-kinase mediated disorder. The process of the present invention preferentially pro